Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

Lenalidomide Plus Bortezomib for Relapsed ... Heartwire from Medscape, November 17, 2009 FDA Approves Romidepsin for Refractory Cutaneous T-Cell Lymphoma The FDA has approved the HDAC inhibitor ...

The drug, lenalidomide, has been shown to improve remission time in eligible patients and prolong life. Prof Graham Jackson from Freeman Hospital called it a "massive change". The disease goes ...

The "Cutaneous T-cell lymphoma - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 25+ companies and 30+ ...